Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 5 % of short-term debt in 2021; threshold 65 %.
-
Late annual account NBB
Fiscal year 2021 was filed 422 days after the legal deadline.
-
Annual account missing NBB
Fiscal year 2022 was expected before 31 July 2023 and has not been filed.
-
Busy address KBO
21 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2021
ReGenesys from Leuven, company number BE0877070337, closed financial year 2021 with a result of € -3 million after tax. For that financial year ReGenesys recorded revenue of € 1 million and equity of € -5 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 26, 2023.
€ -5 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3 million
Profit after tax over the fiscal year.
€ 115,646
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -6 million.
People and assets in 2021
13.2
Average over the fiscal year, from the social balance sheet.
€ 1.3 million
€ 95,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 11,865
Book value of vehicles, furniture and equipment.
Debts at end 2021
None
No bank loans on the last day of the fiscal year.
€ 371,319
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 53 days on average.
€ 136,533
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to ReGenesys?
What happened at ReGenesys in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2021: loss of € 3 million. filed late Source: NBB ↗
- Dan Camardo became a director. NBB
- William Otto Lehmann Jr. stepped down as director. NBB
- Ivor Macleod stepped down as director. NBB
- Ivor Macleod became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
- William Otto Lehmann Jr. became a director. NBB
In short
Pays suppliers within 53 days on average.
A new publication or filing at ReGenesys? We notify you, reason included.
Follow ReGenesysDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ReGenesys is Dan Camardo. The shares are held by Advanced Biotherapeutics Inc. (81.4%) and ReGenesys LLC (18.6%). It owns 99.2% of ReGenesys EU itself.
Directors
According to the 2021 annual accounts
Dan Camardo
Director
since 2022
William Otto Lehmann Jr.
Director
since 2005 · until 2022
Ivor Macleod
Director
since 2021 · until 2022
Shareholders
Advanced Biotherapeutics Inc.
81.4%
ReGenesys LLC
18.6%
Participations
99.2%
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
miDiagnostics
€ 24,934 revenue · 2025
ALIGOS BELGIUM
€ 3.2 million gross margin · 2025
Pledge Therapeutics
€ -97,474 gross margin · 2024
+16 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0877.070.337
- VAT number
- BE 0877.070.337
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- ReGenesys
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 November 2005
- Peppol
- Not registered
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied